Mayne Pharma Group has been growing earnings at an average annual rate of 12.6%, while the Pharmaceuticals industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 5.1% per year.
Key information
12.64%
Earnings growth rate
12.87%
EPS growth rate
Pharmaceuticals Industry Growth
5.95%
Revenue growth rate
5.08%
Return on equity
-23.31%
Net Margin
-20.19%
Next Earnings Update
26 Aug 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Mayne Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:MAYN.F Revenue, expenses and earnings (AUD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
407
-82
272
21
30 Sep 25
408
-86
262
19
30 Jun 25
408
-90
251
18
31 Mar 25
411
-104
260
19
31 Dec 24
414
-118
268
20
30 Sep 24
401
-143
272
20
30 Jun 24
388
-169
276
20
31 Dec 23
319
-274
272
18
30 Sep 23
251
-296
262
17
30 Jun 23
184
-317
251
16
31 Dec 22
59
-257
193
13
30 Sep 22
108
-233
187
12
30 Jun 22
157
-209
182
12
31 Mar 22
250
-151
184
15
31 Dec 21
342
-93
186
19
30 Sep 21
372
-151
179
20
30 Jun 21
401
-208
173
22
31 Mar 21
420
-232
180
22
31 Dec 20
439
-256
187
22
30 Sep 20
448
-174
194
24
30 Jun 20
457
-93
200
25
31 Mar 20
467
-196
210
26
31 Dec 19
478
-300
220
27
30 Sep 19
502
-290
231
28
30 Jun 19
525
-279
241
29
31 Mar 19
543
-118
230
27
31 Dec 18
561
43
219
25
30 Sep 18
546
-46
208
20
30 Jun 18
530
-134
197
15
31 Mar 18
526
-146
196
12
31 Dec 17
521
-158
194
8
30 Sep 17
547
-35
192
8
30 Jun 17
573
89
190
8
31 Mar 17
504
90
173
8
31 Dec 16
435
91
156
8
30 Sep 16
351
64
136
7
30 Jun 16
267
37
115
7
31 Mar 16
238
30
105
7
31 Dec 15
209
23
94
7
30 Sep 15
175
15
77
6
Quality Earnings: MAYN.F is currently unprofitable.
Growing Profit Margin: MAYN.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAYN.F is unprofitable, but has reduced losses over the past 5 years at a rate of 12.6% per year.
Accelerating Growth: Unable to compare MAYN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MAYN.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1%).
Return on Equity
High ROE: MAYN.F has a negative Return on Equity (-23.31%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/23 03:32
End of Day Share Price
2026/08/13 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mayne Pharma Group Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.